EDUCATION CENTER

What is the CJC-1295 + ipamorelin stack?

This protocol pairs a GHRH analog (CJC-1295, with or without DAC depending on the compounded product) with ipamorelin, a selective growth hormone secretagogue. Each peptide is covered in its own education guide; this page explains why they are often prescribed together.

The combination is a clinician-designed compounding strategy, not an FDA-approved branded drug. At Vita Bella it is used only after licensed provider review of goals, labs, and risk.

How the pair may work

GHRH analogs act on GHRH receptors. Ipamorelin acts on ghrelin (GHS-R) receptors. Both can prompt pituitary GH release. Using complementary receptors is the usual rationale for stacking rather than doubling one peptide.

Human studies exist for CJC-1295 and for ipamorelin separately. Large randomized trials of the exact compounded stack for anti-aging or body composition are not the same evidence bar as FDA-labeled GH or tesamorelin.

Stack vs single peptides

Some patients use CJC-1295 or ipamorelin alone. Others use sermorelin or tesamorelin instead of CJC-1295. Stacking is not automatically better; it adds complexity, cost, and more variables if side effects appear.

Your clinician may start with one analog, use a combined vial, or choose tesamorelin when visceral-fat context is the priority.

Potential uses

Clinicians may discuss this stack for recovery, sleep-related recovery, or body-composition support when GH-axis peptides are appropriate.

It does not diagnose or treat adult GH deficiency, and it does not replace nutrition, resistance training, or treatment of sleep apnea.

Candidate assessment

Candidates are typically adults already being evaluated for peptide therapy who understand monitoring and injection technique.

Active malignancy concerns, uncontrolled diabetes, pregnancy, or other red flags may exclude therapy.

Labs & evaluation

Baseline and follow-up IGF-1, glucose/HbA1c, and other markers your clinician selects help decide whether the stack is doing useful work.

If labs or symptoms do not support continuing both peptides, your provider may drop one analog rather than increasing dose.

Forms & dosing

Some pharmacies dispense separate vials; others compound a combined CJC-1295/ipamorelin product. DAC status on the GHRH analog changes frequency.

Do not copy a “CJC/ipa dosage guide” from a blog onto a different formulation. Units are product-specific.

Injection guidance

Use sterile technique, rotate sites, and follow Vita Bella injection resources. Confirm whether the peptides are mixed in one syringe or given separately.

Evening timing is common. If you miss a dose, ask your care team rather than doubling the next injection.

Side effects

Possible effects include injection-site reactions, flushing, headache, water retention, tingling, or increased hunger (more often from the secretagogue).

Report severe edema, vision changes, or symptoms of hyperglycemia promptly.

Safety considerations

Discuss cancer history, diabetes risk, and other GH-axis therapies (including oral MK-677) before stacking.

Athletes subject to anti-doping rules should review current prohibited-list status with their sport’s medical staff. Quality compounding matters more than buying two research vials.

FAQs

References

1. 1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.

2. 2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.

3. 3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797.

4. 4. Molitch ME, et al. Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(6):1587-1609.

Related guides